

Specimen Collected: 13-Oct-21 12:49

APCMYH Panel by NGS, DelDup	Received: 14-Oct-21 12:43	Report/Verified: 19-Oct-21 13:56	
Procedure	Result	Units	Reference Interval
APCMYH Specimen	Whole Blood		
APCMYH Interp	See Note ¹¹		

Test Information

11: APCMYH Interp
 BACKGROUND INFORMATION: APC- and MUTYH-Associated Polyposis Panel, Sequencing and Deletion/Duplication

CHARACTERISTICS: APC-associated polyposis conditions include: familial adenomatous polyposis (FAP), attenuated FAP (AFAP), and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS). FAP: Development of hundreds to thousands of adenomatous colonic polyps beginning in early adolescence; lifetime risk for cancer in untreated individuals is 100 percent. AFAP: Fewer colonic adenomatous polyps (average of 30), which are more proximally located and cancer generally occurs at a later age. MUTYH-associated polyposis (MAP): Development of tens to hundreds of adenomatous colonic polyps with the mean age of presentation at around 50 years.

EPIDEMIOLOGY: The prevalence of FAP has been estimated to be between 1 in 6,850 to 1 in 31,250 live births. Approximately 0.5 percent of colorectal cancer (CRC) cases are caused by FAP. The prevalence of MAP is estimated to be between 1 in 20,000 to 1 in 60,000 individuals. MAP is estimated to account for 0.7 percent of all CRC.

CAUSE: A single pathogenic germline variant in the APC gene is causative for any one of the APC-associated polyposis conditions. Biallelic pathogenic germline variants in the MUTYH gene are causative for MAP.

INHERITANCE: FAP/APC-associated polyposis conditions: Autosomal dominant. MAP: Autosomal recessive.

PENETRANCE: 100 percent in untreated individuals with FAP. The penetrance of AFAP and MAP may be lower, and GAPPS is unknown.

CLINICAL SENSITIVITY: Approximately 93 percent for classic FAP and less than 30 percent for AFAP. Approximately 99 percent for MAP.

GENES TESTED: APC (NM_000038, NM_001127511 Exon 1b only), MUTYH (NM_001128425)

METHODOLOGY: Probe hybridization-based capture of all coding exons and exon-intron junctions of the targeted genes, followed by massively parallel sequencing. Sanger sequencing was performed as necessary to fill in regions of low coverage and confirm reported variants. A proprietary bioinformatic algorithm was used to detect large (single exon-level or larger) deletions or duplications in the indicated genes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Tracy I. George, MD

ARUP Accession: n/a

Report Request ID: 15053955

Printed: 19-Oct-21 13:58

Page 1 of 2

Test Information

i1: APCMYH Interp

Large deletions/duplications were confirmed using an orthogonal exon-level microarray. Human genome build 19 (Hg 19) was used for data analysis.

ANALYTICAL SENSITIVITY/SPECIFICITY: The analytical sensitivity is approximately 99 percent for single nucleotide variants (SNVs) and greater than 93 percent for insertions/duplications/deletions (Indels) from 1-10 base pairs in size. Indels greater than 10 base pairs may be detected, but the analytical sensitivity may be reduced. Deletions of 2 exons or larger are detected with sensitivity greater than 97 percent; single exon deletions are detected with 62 percent sensitivity. Duplications of 3 exons or larger are detected at greater than 83 percent sensitivity. Specificity is greater than 99.9 percent for all variant classes.

LIMITATIONS: A negative result does not exclude a diagnosis of familial adenomatous polyposis (FAP), other APC-associated polyposis conditions, or MUTYH-associated polyposis. A negative result does not exclude all genetic diagnoses. This test only detects variants within the coding regions and intron-exon boundaries of the APC and MUTYH genes. Deletions/duplications/insertions of any size may not be detected by massively parallel sequencing. Regulatory region variants and deep intronic variants will not be identified. Precise breakpoints for large deletions or duplications are not determined in this assay and single exon deletions/duplications may not be detected based on the breakpoints of the rearrangement. The actual breakpoints for the deletion or duplication may extend beyond or be within the exon(s) reported. This test is not intended to detect duplications of 2 or fewer exons in size, though these may be identified. Single exon deletions are reported but called at a lower sensitivity. Diagnostic errors can occur due to rare sequence variations. In some cases, variants may not be identified due to technical limitations caused by the presence of pseudogenes, repetitive, or homologous regions. This test is not intended to detect low-level mosaic or somatic variants, gene conversion events, complex inversions, translocations, mitochondrial DNA (mtDNA) mutations, or repeat expansions. Interpretation of this test result may be impacted if this patient has had an allogeneic stem cell transplantation. Non-coding transcripts were not analyzed.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Tracy I. George, MD

ARUP Accession: n/a

Report Request ID: 15053955

Printed: 19-Oct-21 13:58

Page 2 of 2